Pirenzepine exhibits anti-prostate cancer activity and enhances checkpoint inhibitor-based immunotherapy by targeting STING
Our results revealed that PZP impaired the malignant biological behavior of PCa and enhanced antitumor immunity. These findings may provide a theoretical basis for combining PZP with anti-PD1 immune checkpoint blockade therapy on PCa.
Authors
- Jun Xu (ORCID: https://orcid.org/0000-0002-6080-118X)
- Jin Li (ORCID: https://orcid.org/0000-0002-6131-456X)
- Junwen Zhang
- Yongsheng Yu
Institutions
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1186/s40001-025-03520-4
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Guangzhou Medical University
- Guangzhou Municipal Science and Technology Project